Keratoconus

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Wednesday, March 27, 2024
Science, Other Science, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Momentum, YAG, Toric, Failure, IOP, Retinal, Glaucoma, Exercise, DSM-IV codes, Neuropathic pain, ASCRS, History, Sale, Contact, Dry, Refraction, Bausch & Lomb, Eye, System, Keratoconus, Medication discontinuation, Pain, Corneal topography, Telecanthus, Astigmatism, Aphakia, Correction, Uveitis, Surgeon, Diabetes, Risk, Eye injury, CTK, Retinal detachment, Side, Trial of the century, Visual acuity, Diagnosis, Safety, Contraindication, Emmetropia, Vision, Taste, Dry eye syndrome, Intraocular lens, Presbyopia, Real, Floater, Magnetic resonance, Contrast (vision), Human, GLARE, Infection, Use, FDA, Ranibizumab, Muscular dystrophy, Sickle cell disease, Refractive surgery, Retina, Direction, IDE, Allergy, User, Society, Bleeding, Autoimmune disease

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points: 
  • In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
  • Bausch + Lomb activities at ASCRS:
    “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
  • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
  • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.

Bausch + Lomb Receives FDA Approval for TENEO™ Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery

Retrieved on: 
Monday, January 8, 2024
FDA, General Health, Optical, Health, IOP, Telecanthus, Patient, Ophthalmology, Failure, Corneal topography, Food, Autoimmune disease, Contraindication, Risk, Floater, Sale, Near-sightedness, CTK, Pain, Retinal detachment, User, Bleeding, Surgeon, Diabetes, Dry, Eye, Side, Dry eye syndrome, Posture, Laser, Visual acuity, Neuropathic pain, Engineering, Infection, Use, Keratoconus, Safety, Magnetic resonance, Bausch & Lomb, Glaucoma, Hospital

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. Food and Drug Administration (FDA) has approved the TENEO Excimer Laser Platform for laser-assisted in situ keratomileusis (LASIK) vision correction surgery for myopia and myopic astigmatism (nearsightedness and nearsightedness with astigmatism)*.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. Food and Drug Administration (FDA) has approved the TENEO Excimer Laser Platform for laser-assisted in situ keratomileusis (LASIK) vision correction surgery for myopia and myopic astigmatism (nearsightedness and nearsightedness with astigmatism)*.
  • This feature helps to ensure the laser ablation pattern is not negatively impacted by a patient's eye movement and helps achieve outstanding post-operative outcomes.
  • The platform’s high-speed laser operates at 500Hz, the fastest ablation time of all excimer lasers available in the United States at approximately 1.2 seconds per diopter.
  • “FDA approval of TENEO represents a major milestone for the advancement of laser vision correction technology in the United States,” said George Waring IV, M.D., ophthalmologist and founder and medical director, Waring Vision Institute, Mt.

T. Hunter Newsom, MD Returns to His Hometown and Joins His Father, Dr. William Newsom of Eye Associates of Gainesville, Bringing Innovative Technologies to Alachua County

Retrieved on: 
Friday, December 15, 2023
ICL, Research, Keratoconus, Patient, University, Collagen, FDA, CXL, Aphakia, Cataract, Mayo Clinic, Lens, EVO, Health, LAL, Telescopic sight, Hunting, Dentistry, MD, LASIK, Ophthalmology

GAINESVILLE, Fla., Dec. 15, 2023 /PRNewswire-PRWeb/ -- T. Hunter Newsom, MD, a distinguished Tampa-based ophthalmologist and founder of Newsom Eye, has returned to his hometown of Gainesville, Florida, and is adding a new location, Eye Associates of Gainesville. Dr. T. Hunter Newsom brings a wealth of expertise in advanced eye care, including the pioneering Light Adjustable Lens and Collagen Cross-Linking (CXL) for keratoconus patients, and will be working alongside his father, William Newsom, MD.

Key Points: 
  • T. Hunter Newsom, MD, a board-certified ophthalmologist, specializes in cataract, LASIK surgery, and the EVO Implantable Contact Lens (ICL) procedures.
  • T. Hunter Newsom, MD, alongside his wife Stacy Newsom, both alumni of the University of Florida, cherish deep ties with the community.
  • Under T. Hunter Newsom MD's leadership, Newsom Eye has been at the forefront of ophthalmological advancements, participating in multiple FDA studies.
  • The collaboration between T. Hunter Newsom, MD and Eye Associates of Gainesville marks a new chapter in providing top-tier eye care in the region.

Epion Therapeutics Initiates Phase 3 Clinical Trials for Minimally-Invasive Keratoconus Treatment

Retrieved on: 
Tuesday, October 31, 2023
Science, Other Science, Research, Optical, General Health, Health, Clinical Trials, Other Health, Keratoconus, Patient, Prevalence, Publication, HIV disease progression rates, Syd Arthur, Epithelium, Safety, Therapy, Pain, Diagnosis, Pharmaceutical industry

Epion Therapeutics (Epion) announced the commencement of its Phase 3 Apricity trials for EpiSmart™, the company’s minimally-invasive keratoconus therapy.

Key Points: 
  • Epion Therapeutics (Epion) announced the commencement of its Phase 3 Apricity trials for EpiSmart™, the company’s minimally-invasive keratoconus therapy.
  • The randomized, masked, placebo-controlled Apricity trials will evaluate the safety and efficacy of EpiSmart, building upon the promising results observed in Phase 2 clinical trials.
  • Epion plans to enroll 800 subjects at over 20 investigational sites throughout the US in two concurrent Apricity Phase 3 trials.
  • Patients in the Phase 2 trials of EpiSmart received simultaneous, bilateral treatment and experienced a very low rate of adverse events.

CXL Ophthalmics Announces New Name and Vision as Epion Therapeutics

Retrieved on: 
Thursday, July 6, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Infection, Cornea, Partnership, CXL, Prevalence, Keratoconus, Quality of life, HIV disease progression rates, Patient, Standard of care, Risk, Diagnosis, Therapy, Medical imaging, Pharmaceutical industry, Epion

CXL Ophthalmics, Inc., a leading innovator in corneal disease treatments, is pleased to announce its new name as Epion Therapeutics, Inc.

Key Points: 
  • CXL Ophthalmics, Inc., a leading innovator in corneal disease treatments, is pleased to announce its new name as Epion Therapeutics, Inc.
  • This vision and strategic direction precede enrollment in Epion’s Phase 3 Trials of the EpiSmart™ System.
  • Keratoconus is a corneal disorder characterized by thinning and conical protrusion of the cornea, causing distorted vision.
  • Epion Therapeutics is pioneering early intervention with the goal of treating patients upon diagnosis, eliminating the requirement to wait for disease progression,” said Michael Belin, Chief Medical Officer at Epion.

Glaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on)

Retrieved on: 
Monday, June 5, 2023
Health, Health Technology, Clinical Trials, Pharmaceutical, Optical, Biotechnology, GKOS, Glaucoma, Food, NDA, Corneal topography, Retina, Keratoconus, Corporation, Patient, EPI, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Safety, Pharmaceutical industry, 1870 Glaukos

“We appreciate the commitment and dedication of the clinical investigators, who played a vital role in helping to achieve this enrollment milestone ahead of our original timing expectations.

Key Points: 
  • “We appreciate the commitment and dedication of the clinical investigators, who played a vital role in helping to achieve this enrollment milestone ahead of our original timing expectations.
  • The study eyes were randomized in a 2:1 ratio to receive Epioxa therapy or placebo and sham procedure control treatment.
  • Results from this second Phase 3 confirmatory pivotal trial together with the already-completed first Phase 3 pivotal trial are expected to support Glaukos’ targeted NDA submission for Epioxa by the end of 2024.
  • As a reminder, the U.S. FDA has confirmed Glaukos’ first Phase 3 pivotal trial for Epioxa, which met the pre-specified primary efficacy endpoint, would be adequate to support the submission and review of an eventual NDA, in conjunction with this second Phase 3 trial.

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Monday, May 1, 2023
General Health, Medical Devices, Health, Pharmaceutical, Optical, GKOS, Glaucoma, Collagen, Refractive surgery, Corneal ectatic disorders, ASCRS, Retina, American Society of Cataract and Refractive Surgery, Corporation, Art, Physician, Cataract, Borat Subsequent Moviefilm, Society, NYSE, Pharmaceutical industry, Keratoconus, Ectasia

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held May 5 – 8, 2023 in San Diego, CA.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held May 5 – 8, 2023 in San Diego, CA.
  • Glaukos will be exhibiting onsite at booth #1237.
    iStent inject® Trabecular Micro-Bypass Stent Implantation with Cataract Extraction in Open-Angle Glaucoma: Long-Term Results
    10-Year Follow-up for Collagen Cross-Linking in Keratoconus and Ectasia: Comparison of Outcomes with Subsequent Topography-Altering Surgery
    Customized Transepithelial Cross-Linking for Keratoconus: 2-Year Follow-up
    Keratoconus State of the Art: New Cutting-Edge Treatments for Corneal Ectasia (IC-105)
    The ASCRS Annual Meeting is among the largest gatherings of anterior segment physicians, medical personnel and industry executives in the ophthalmic industry.
  • All educational content of the ASCRS annual meeting is planned by its program committee.
  • ASCRS does not endorse, promote, approve or recommend the use of any products, devices or services.

CXL Ophthalmics’ CMO To Deliver Plenary Session at 1st Annual International Keratoconus Academy Symposium

Retrieved on: 
Friday, April 21, 2023
Biotechnology, Optical, Health, Clinical Trials, CXL, Ophthalmology, Keratoconus, Best practice, MD, Patient, 3rd Plenary Session of the 11th Central Committee of the Chinese Communist Party, Prognosis, IKA, Medical device, Hotel, McDowell Mountains

CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, announced today that CMO Michael W. Belin, MD, will present the Plenary Session at the 1st Annual International Keratoconus Academy (IKA) Symposium.

Key Points: 
  • CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, announced today that CMO Michael W. Belin, MD, will present the Plenary Session at the 1st Annual International Keratoconus Academy (IKA) Symposium.
  • The symposium will be held on April 22 and 23 in Scottsdale, AZ, and will convene optometrists, ophthalmologists, and industry experts involved in the management and treatment of keratoconus.
  • In addition to delivering the Plenary Session, Dr. Belin will present during the Best Practices in Keratoconus Diagnostics II session.
  • “The first annual IKA symposium on the treatment and management of keratoconus marks an important step in advancing the conversation around this vision-threatening condition,” said Dr. Belin.

Global Artificial Corneal Implants Market Report 2023: Huge Patient Pool and Limited Supply of Donor Tissue Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 23, 2023
Medical Devices, Health, Cornea, COVID-19, Research, USD, Chapter Three, Transplant, Photokeratitis, Patient, Growth, Medical device, Dentistry, Keratoconus

The global artificial corneal implants market size is expected to reach USD 118.3 billion by 2030, registering a CAGR of 7.1% from 2023 to 2030.

Key Points: 
  • The global artificial corneal implants market size is expected to reach USD 118.3 billion by 2030, registering a CAGR of 7.1% from 2023 to 2030.
  • Introduction of new products in the market that are aimed to reduce the post-surgery complications is the key factor driving the growth of the artificial corneal implants market.
  • In addition, the continuously growing patient pool and lack of human cornea donors create a huge demand and supply gap.
  • On the other hand, increasing corneal disorders that require a corneal transplant, as well as rising awareness regarding artificial corneal implants in Asia Pacific, are factors expected to boost market growth over the forecast period.

CXL Ophthalmics Appoints Tiffany Haynes as Vice President of Clinical Operations

Retrieved on: 
Tuesday, March 14, 2023
Medical Devices, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Keratoconus, Haynes, Johnson & Johnson Vision, Medical Affairs Bureau, Risk, Abbott, Ophthalmology, Patient, CXL, Diagnosis, Safety, Clinical trial, Paratriathlon, Pharmaceutical industry

CXL Ophthalmics , Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today announced that Tiffany Haynes has been appointed as Vice President of Clinical Operations.

Key Points: 
  • CXL Ophthalmics , Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today announced that Tiffany Haynes has been appointed as Vice President of Clinical Operations.
  • With more than 25 years of experience in ophthalmology, Haynes previously served as Global Director, Medical Affairs for Johnson & Johnson Vision.
  • There, she was responsible for worldwide clinical training and competency on ophthalmic medical devices, managing more than 50 clinical trainers globally.
  • “Tiffany brings strong global medical affairs, ophthalmology management, regulatory and clinical trial experience to the CXLO team,” commented Michael D. Webb, President and Chief Executive Officer of CXL Ophthalmics.